WSK-V102E

WSK-V102E is a recombinant protein subunit vaccine developed by West China Hospital of Sichuan University for the prevention of COVID-19. It is designed as a booster dose to enhance immunity in individuals who have previously completed a primary vaccination series. The vaccine utilizes a recombinant protein platform, typically targeting the spike protein of SARS-CoV-2 to induce neutralizing antibodies and T-cell responses. WSK-V102E is part of a broader development program (including WSK-V102F and WSK-V106) aimed at addressing evolving variants of the virus. As of 2024, it is undergoing clinical evaluation in China to assess its safety, immunogenicity, and efficacy as a heterologous or homologous booster.

Other names

WSK-V102E recombinant COVID-19 vaccineWSK-V-102E recombinant COVID-19 vaccineWSK-V 102E recombinant COVID-19 vaccine